• Kane Biotech will host a virtual commercial update webcast on Sept. 16, 2026 at 11:00 a.m. ET.
• Presentation will outline the plan to drive recurring revenue from revyve wound-care products through clinical adoption, channels, sales execution.
• Interim CEO Robert Huizinga will deliver the operational update; board chair Philip Renaud will participate.
• Mount Sinai surgeon John C. Lantis will provide a clinical perspective on chronic wounds, biofilms, revyve use in venous leg ulcers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kane Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090705PRIMZONEFULLFEED9823370) on September 09, 2026, and is solely responsible for the information contained therein.